• Explore /
  • Poster
  • / Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.

Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.

Abstract Video & Slides Poster

Authors

null

Yuqin Song

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), the Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China

Yuqin Song , Jun Zhu , Ningjing Lin , Mingzhi Zhang , Hai Bai , Hui Liu , Jie Cui , Xiaoyan Ke , Huilai Zhang , Lihong Liu , Dongmei Yan , Yongsheng Jiang , Aimin Zang , Junyuan Qi , Li Wang , Zhuogang Liu , Bing Xu , Ying Zhang , Zhihui Zhang , Haijin Meng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03655483

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8033)

DOI

10.1200/JCO.2020.38.15_suppl.8033

Abstract #

8033

Poster Bd #

366

Abstract Disclosures

Similar Posters

First Author: Jie Xu

First Author: Philippe Armand

First Author: Minsuk Kwon

First Author: Chunmeng Wang